Tracer library / [99mTc]Tc-PSMA-I&S

[99mTc]Tc-PSMA-I&S

Also written as [99mTc]Tc-PSMA-I&S

Radionuclide: Tc-99m t½ 360.6 min
Modality: SPECT
Production route: —
Stage: —
Syntheses indexed: 4

Prostate cancer Other radioligand therapy Radioguided / image-guided surgery (intraoperative)

What it is

Compound class: PSMA-targeting urea-based peptidomimetic inhibitor (2-mercaptoacetyl-D-Ser-D-Ser-D-Ser-D-Tyr-D-2-Nal-D-Lys(Sub-L-Lys-Urea-L-Glu))
Target / mechanism: Targets prostate-specific membrane antigen (PSMA) PMID 32382945
Clinical application: SPECT imaging and radioguided surgery of prostate cancer PMID 37901160
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Scintomics GRP 4V Scintomics	vendor cassette	SPE	58.7 ± 1.5%	93.0 ± 0.3%	PSMA-I&S piCHEM, Raaba-Grambach, Austria	36677636 2023 Molecules a Scintomics GRP 4 V module - The mean radiochemical yield was calculated based on the starting activity (2378 ± 450 MBq) and was 58.7 ± 1.5%.
Scintomics GRP / GRP-3V Scintomics	vendor cassette	SPE	75.9% decay-corrected	96.3% 97.6%, and 98.2%	PSMA-I&S piCHEM, Raaba-Grambach, Austria	32358637 2020 EJNMMI Radiopharm Chem Automated labeling was performed with a Scintomics GRP 3 V module (Scintomics GmbH, Fürstenfeldbruck, Germany). - The mean yield of produced [99mTc]Tc-PSMA was 75.9% of the initial activity at start of the labeling (corrected for decay, range 74.8–77.9%)
Kit-based preparation	vendor cassette	—	—	>95%	PSMA-I&S	40732291 2025 Pharmaceuticals (Basel) Radiolabeling was performed in a kit-based radiolabeling procedure.
Kit-based preparation	—	none	92.05% ± 2.20%	92.05 ± 2.20	PSMA-I&S Tecnonuclear-Eckert Ziegler, Argentina	37901160 2023 Front Chem The PSMA-I&S cold kit was produced and supplied by Tecnonuclear-Eckert Ziegler (Argentina). - obtaining RCY of 92.05% ± 2.20% (n = 5)

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center.
2020 · EJNMMI Res · Clinical study
Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
2017 · J Nucl Med · Clinical study

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Tecnonuclear-Eckert Ziegler, piCHEM
Typical final purification: —

Need this precursor?We can point you to suppliers for [99mTc]Tc-PSMA-I&S, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impurities

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [99mTc]Tc-PSMA-I&S.

Get in touch

Notes

Added from reverse module search (stage 6); 6 article(s) with Tc-99m. Compound class inferred from precursor name (not stated outright) -- PMID 32358637: '2-mercaptoacetyl-D-Ser-D-Ser-D-Ser--D-Tyr-D-2-Nal-D-Lys (SUB-L-Lys-Urea-L-Glu)'. | Stage 28: added indication(s) oth-radioguided-surgery from consolidated missing-rubric review.